Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4 update was “notable” with several upcoming data catalysts, the analyst tells investors in a research note. TX112 data to-date is “impressive”, while the competitor data from CB-010 and cema-cel – both in the first half – could be indirect catalysts for CRSP, Truist added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics AG: Strong Financial Position and Strategic Advancements Justify Buy Rating
- Crispr Therapeutics upgraded to Hold from Sell at TD Cowen
- Crispr Therapeutics price target raised to $56 from $55 at Barclays
- Crispr Therapeutics AG’s Financial Challenges: Sell Rating Due to Casgevy Program Burden
- Crispr Therapeutics AG: Strategic Collaborations and Promising Pipeline Drive ‘Buy’ Rating